Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
McKinsey
Johnson and Johnson
Colorcon
AstraZeneca

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Patent: 9,862,767

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 9,862,767
Title:Therapeutic methods using anti-CD200 antibodies
Abstract: The present disclosure relates to anti-CD200 antibodies and to use of the antibodies in methods for treating autoimmune disorders and cancer. Also featured are biomarkers for use in selecting or prescribing a treatment modality for a patient with an autoimmune disorder and/or cancer. In addition, the disclosure features methods of treatment using an anti-CD200 antibody in combination with one or more additional therapeutic agents such as an anti-CD20 therapeutic agent.
Inventor(s): Rother; Russell P. (Oklahoma City, OK), Yan; Yan (Cheshire, CT)
Assignee: Alexion Pharmaceuticals, Inc. (New Haven, CT)
Application Number:14/739,862
Patent Claims:see list of patent claims

Details for Patent 9,862,767

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Alexion Pharmaceuticals, Inc. (New Haven, CT) 2030-02-11 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Alexion Pharmaceuticals, Inc. (New Haven, CT) 2030-02-11 RX Orphan search
Genentech Inc OCREVUS ocrelizumab INJECTABLE;INJECTION 761053 001 2017-03-28   Start Trial Alexion Pharmaceuticals, Inc. (New Haven, CT) 2030-02-11 RX search
Glaxo Grp Ltd ARZERRA ofatumumab INJECTABLE; INJECTION 125326 001 2009-10-26   Start Trial Alexion Pharmaceuticals, Inc. (New Haven, CT) 2030-02-11 RX Orphan search
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   Start Trial Alexion Pharmaceuticals, Inc. (New Haven, CT) 2030-02-11 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,862,767

Country Patent Number Publication Date
World Intellectual Property Organization (WIPO) 2011100538 Aug 18, 2011
United States of America 2013189258 Jul 25, 2013
United States of America 2016009803 Jan 14, 2016
United States of America 9085623 Jul 21, 2015
Singapore 182823 Sep 27, 2012
Russian Federation 2012138703 Mar 20, 2014
New Zealand 601580 Nov 28, 2014
>Country >Patent Number >Publication Date

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Baxter
Medtronic
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.